Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Di Giambenedetto

Showing results (1-10 of 200) with videos related to

Pageof 20
Sort By:
Diagnostics (Basel, Switzerland)|January 21, 2022
Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical PracticeSimone Belmonti, Simona Di Giambenedetto, Francesca Lombardi
Expert Review of Anti-Infective Therapy|February 19, 2020
Dolutegravir plus lamivudine for the treatment of HIV-1 infectionArturo Ciccullo, Gianmaria Baldin, Alberto Borghetti, et al.
Diagnostic Microbiology and Infectious Disease|November 23, 2011
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic areaAlessandro D'Avino, Simona Di Giambenedetto, Massimiliano Fabbiani, et al.
Expert Opinion on Drug Safety|May 21, 2021
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIVArturo Ciccullo, Gianmaria Baldin, Cristina Putaggio, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 11, 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialUmberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, et al.
AIDS and Behavior|September 26, 2022
Home Care Assistance: Has Covid-19 had an Impact on the Complex Management of HIV Patients?Alex Dusina, Francesca Lombardi, Enrica Tamburrini, et al.
Therapeutic Drug Monitoring|February 15, 2013
Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samplesSerena Fortuna, Enzo Ragazzoni, Lucia Lisi, et al.
Le Infezioni in Medicina|September 13, 2020
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapyFrancesca Lombardi, Simone Belmonti, Alberto Borghetti, et al.
Antiviral Therapy|June 9, 2006
Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trialAndrea De Luca, Simona Di Giambenedetto, Antonella Cingolani, et al.
Journal of Clinical Microbiology|August 6, 2005
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapyAngela Marzocchetti, Simona Di Giambenedetto, Antonella Cingolani, et al.
Pageof 20

Showing results (1-10 of 200) with videos related to

Sort By:
Pageof 20
Diagnostics (Basel, Switzerland)|January 21, 2022
Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical PracticeSimone Belmonti, Simona Di Giambenedetto, Francesca Lombardi
Expert Review of Anti-Infective Therapy|February 19, 2020
Dolutegravir plus lamivudine for the treatment of HIV-1 infectionArturo Ciccullo, Gianmaria Baldin, Alberto Borghetti, et al.
Diagnostic Microbiology and Infectious Disease|November 23, 2011
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic areaAlessandro D'Avino, Simona Di Giambenedetto, Massimiliano Fabbiani, et al.
Expert Opinion on Drug Safety|May 21, 2021
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIVArturo Ciccullo, Gianmaria Baldin, Cristina Putaggio, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 11, 2017
Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trialUmberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto, et al.
AIDS and Behavior|September 26, 2022
Home Care Assistance: Has Covid-19 had an Impact on the Complex Management of HIV Patients?Alex Dusina, Francesca Lombardi, Enrica Tamburrini, et al.
Therapeutic Drug Monitoring|February 15, 2013
Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samplesSerena Fortuna, Enzo Ragazzoni, Lucia Lisi, et al.
Le Infezioni in Medicina|September 13, 2020
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapyFrancesca Lombardi, Simone Belmonti, Alberto Borghetti, et al.
Antiviral Therapy|June 9, 2006
Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trialAndrea De Luca, Simona Di Giambenedetto, Antonella Cingolani, et al.
Journal of Clinical Microbiology|August 6, 2005
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapyAngela Marzocchetti, Simona Di Giambenedetto, Antonella Cingolani, et al.
Pageof 20